

REMARKS

Claim 6 has been amended to delete the intended use and to recite a pharmaceutically acceptable carrier or excipient, as supported at least at page 25, second full paragraph.

Claims 7-10 have been canceled as not further limiting claims 1-5.

In response to the Restriction Requirement, Applicant elects Group IV. This election is made with traverse only in that in view of the amendment to claim 6, removing the intended use, Applicant submits that claim 6 should be examined along with claims 1-5. Note also that in the description of Group IV, "n" should be "m," i.e. $m = 0$.

In response to the Election of Species with respect to Z, Applicant elects Z = unsubstituted or substituted heteroaryl. The claims readable on the elected species are claims 1, 3, and 4.

In addition, the Examiner is requested, respectfully, to rejoin the method claims upon indication that claims 1 to 5 are allowable.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES
& PRELIMINARY AMENDMENT

U.S. Appln. No.: 10/518,405

Atty. Docket No.: Q85416

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Susan J. Mack
Registration No. 30,951

Date: March 15, 2007